Lettmann Jason 4
4 · ALX ONCOLOGY HOLDINGS INC · Filed Feb 21, 2025
Insider Transaction Report
Form 4
Lettmann Jason
DirectorCHIEF EXECUTIVE OFFICER
Transactions
- Sale
Common Stock
2025-02-19$1.15/sh−2,159$2,483→ 170,270 total
Footnotes (3)
- [F1]The shares were sold to satisfy the reporting person's tax liability in connection with the vesting of restricted stock units.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.15 to $1.16, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.
- [F3]Includes 3,000 shares acquired under the Issuer's employee stock purchase plan on December 31, 2024.